Positions

Overview

  • I am a Physician Scientist at the University of Alabama at Birmingham Comprehensive Cancer Center. I conduct clinical and translational research in breast cancer and I am the principal investigator for many clinical trials. My research in the lab focuses on translational (mRNA to protein) dysregulation and intends to address a critical, yet elusive, fundamental biologic question, i.e. in a competing pool of mRNAs, how breast cancer cells mis-prioritize the translation of certain mRNAs that allow for their proliferation and survival. With the support from ASCO Young Investigator Award and currently Susan G Komen Career Catalyst Award, I have adapted next-generation sequencing methods to visualize translational regulation at a global genomic scale. The knowledge gained from this work will advance our understanding of challenging clinical problems including tumor persistence, growth, and therapeutic resistance.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2018 Translational control of the undifferentiated phenotype in ER‑positive breast tumor cells: Cytoplasmic localization of ERα and impact of IRES inhibition.Oncology Reports.  39:2482-2498. 2018
    2017 Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application.Oncotarget.  8:16052-16074. 2017
    2017 Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development.Frontiers in Oncology.  7:158. 2017
    2016 IRES inhibition induces terminal differentiation and synchronized death in triple-negative breast cancer and glioblastoma cells.Tumor Biology.  37:13247-13264. 2016
    2015 Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat?Seminars in Oncology.  42:e67-e79. 2015
    2015 Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.Clinical Cancer Research.  21:2771-2779. 2015
    2015 TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.Clinical Cancer Research.  21:2722-2729. 2015
    2015 Small molecule inhibitors of IRES-mediated translation.Cancer Biology and Therapy.  16:1471-1485. 2015
    2014 Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).Clinical immunotherapeutics.  28:253-263. 2014
    2013 Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience.Acta hepato-splenologica.  60:1611-1623. 2013
    2013 Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.Cancer Biotherapy and Radiopharmaceuticals.  28:370-379. 2013
    2013 A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancer.Seminars in Oncology.  40:135-144. 2013
    2012 Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.Therapeutic Advances in Hematology.  3:209-225. 2012
    2012 Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.Cancer.  118:1422-1428. 2012
    2012 By the pricking of my thumbs, something wicked this way comes: sporadic cancers versus eponymous hereditary cancer predisposition syndromes.Journal of the National Comprehensive Cancer Network.  10:7-13. 2012
    2011 A case of acute promyelocytic leukemia without RARα rearrangement and apparently normal cytogenetics.Clinical Lymphoma, Myeloma and Leukemia.  11:521-524. 2011
    2011 How do I treat "triple-negative" disease.Current Treatment Options in Oncology.  12:369-388. 2011
    2011 Common cardiovascular medications in cancer therapeutics.Pharmacology and Therapeutics.  130:177-190. 2011
    2011 Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience.Cancer.  117:77-85. 2011
    2011 The changing perspective of cardiology in cancer care.Expert Review of Cardiovascular Therapy.  9:1-3. 2011
    2010 Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression.Virology Journal.  7:256. 2010
    2010 Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.Drug Safety.  33:171-187. 2010
    2010 Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.Clinical Cancer Research.  16:1149-1158. 2010
    2010 Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?Oncologist.  15:130-141. 2010
    2009 Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.Journal of Pediatric Hematology/Oncology.  31:803-811. 2009
    2009 Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience.Journal of Clinical Endocrinology and Metabolism.  94:4423-4432. 2009
    2009 Molecular basis of statin-associated myopathy.Atherosclerosis.  202:18-28. 2009
    2008 Coenzyme Q10 depletion: etiopathogenic or predisposing factor in statin associated myopathy?American Journal of Cardiology.  101:1071. 2008
    2007 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course.Leukemia Research.  31:691-694. 2007
    2004 Pelvic reconstruction of the retroperitoneum after abdominoperineal resection of the rectum using full-thickness skin grafts.Techniques in Coloproctology.  8 Suppl 1:s85-s88. 2004

    Chapter

    Year Title Altmetric
    2013 Brentuximab vedotin (SGN-35) for CD30-positive malignancies.  161-175. 2013
    2013 CDX-011 (Glembatumumab vedotin, CR011-vcMMAE).  211-220. 2013

    Research Overview

  • Breast Cancer Translational research Gene-specific translational dysregulation
  • Principal Investigator On

  • UAB17127:A phase Ib trial of fulvestrant, palbociclib (CDK4/6 inhibitor) and erdafitinib (JNJ- 42756493, pan-FGFR tyrosine kinase inhibitor) in ER+/HER2–/FGFR-amplified metastatic breast cancer (MBC)  awarded by VANDERBILT UNIVERSITY 2018 - 2023
  • Private Grant  awarded by ZYMEWORKS BIOPHARMACEUTICALS 2018 - 2023
  • Private Grant  awarded by INNOCRIN PHARMACEUTICALS, INC. 2016 - 2021
  • UAB 1643- A Randomized Phase II Trial of Fulvestrant With or Without Ribociclib After Progression on Aromatase Inhibition Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients with Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer  awarded by Columbia University 2016 - 2020
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2015 - 2020
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2015 - 2019
  • Dissecting IRES Mediated Translation in Breast Cancer  awarded by Komen (Susan G.) Breast Cancer Foundation 2015 - 2019
  • TBCRC 026/UAB 1367: A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer (ML28190)  awarded by Johns Hopkins University 2014 - 2019
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2013 - 2019
  • Private Grant  awarded by PHARMACYCLICS, INC. 2015 - 2018
  • Private Grant  awarded by INCYTE CORPORATION 2014 - 2016
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2014 - 2016
  • Private Grant  awarded by ARQULE 2014 - 2016
  • UAB 1198: A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel with or without RAD001 in Patients with Triple-Negative Locally Advanced Breast Cancer  awarded by VANDERBILT UNIVERSITY 2015
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2015
  • Investigator On

  • Private Grant  awarded by GlaxoSmithKline 2017 - 2025
  • Private Grant  awarded by Pfizer Pharmaceuticals 2017 - 2025
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2018 - 2023
  • Private Grant  awarded by ELI LILLY AND COMPANY 2018 - 2023
  • Private Grant  awarded by Genentech 2018 - 2023
  • Private Grant  awarded by CALITHERA BIOSCIENCES INC 2017 - 2022
  • Plasma Tumor DNA and Pathologic Complete Response in Early-Stage, High-Risk Breast Cancer  awarded by Johns Hopkins University 2017 - 2022
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2016 - 2022
  • TBCRC 035 UAB 15114: Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II Study with Pharmacodynamics Markers (TBCRC 35)  awarded by Johns Hopkins University 2016 - 2021
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS 2016 - 2021
  • Private Grant  awarded by TESARO, INC. 2016 - 2021
  • Private Grant  awarded by Genentech 2016 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2017 - 2021
  • Private Grant  awarded by CASCADIAN THERAPEUTICS 2016 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2021
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2016 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2021
  • Private Grant  awarded by EMD SERONO 2016 - 2021
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2016 - 2021
  • TBCRC030 - A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker  awarded by Johns Hopkins University 2014 - 2019
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2019
  • UAB 1430: Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Anastrozole in Women with Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer  awarded by Washington University 2014 - 2019
  • UAB 1761: A Randomized, Placebo-Controlled, Double-Blind, Phase II trial of Nanoparticle Albumin-Bound Paclilaxel (Nab-Paclilaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple Negative Breast Cancer.  awarded by University of Chicago 2017 - 2019
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2014 - 2019
  • Utilizing Multiomic Advanced Diagnostics to Identify Palbociclib Response Predictors and a Post-treatment Multiomic Signature for Patients with ER+/HER2- Metastatic Breast Cancer  awarded by THE SIDE-OUT FOUNDATION 2017 - 2019
  • Private Grant  awarded by CELLDEX THERAPEUTICS, INC. 2014 - 2019
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2019
  • TBCRC 033 UAB 1568: A Randomized Phase II study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage 1 HER2-Positive Breast Cancer (ATEMPT Trial)  awarded by Dana-Farber Cancer Institute 2015 - 2018
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2013 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2018
  • TBCRC 037 UAB 1644:A Trial of Endocrine Response In Women with Invasive Lobular Breast Cancer.  awarded by University of Pittsburgh 2016 - 2018
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2015 - 2017
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2017
  • Private Grant  awarded by ONCOTHYREON, INC. 2015 - 2016
  • Private Grant  awarded by DAIICHI SANKYO PHARMA DEVELOPMENT 2014 - 2016
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2015
  • Targeting IRES Mediated Translation in Cancer Therapeutics  awarded by American Society of Clinical Oncology 2012 - 2014
  • Education And Training

    Full Name

  • Christos Vaklavas
  • Blazerid

  • cvaklava